Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Studies Stopped for Daratumumab/Checkpoint Inhibitor Combos in NSCLC, Myeloma

May 29th 2018

Two separate early-phase clinical trials exploring daratumumab in combination with either a PD-1 inhibitor for multiple myeloma or a PD-L1 inhibitor for non–small cell lung cancer were terminated following a planned interim analysis.

Dr. Htut on Immunotherapy in Multiple Myeloma

May 25th 2018

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of immunotherapy in the treatment of patients with multiple myeloma.

Selinexor Tested in Combination With Standard Therapy in Multiple Myeloma

May 25th 2018

The BOSTON trial is randomizing patients with relapsed/refractory multiple myeloma to a triplet combination of selinexor (KPT-330), bortezomib (Velcade), and dexamethasone versus a combination of bortezomib and dexamethasone.

New Upfront Strategies Emerge for Multiple Myeloma

May 18th 2018

A. Keith Stewart, MB, ChB, and a panel of hematology experts review data concerning emerging frontline strategies for multiple myeloma that were presented at the 2017 ASH Annual Meeting.

ASCO Panel Sees Greater Utility for Bone-Modifying Agents in Myeloma

May 17th 2018

In updated guidelines exploring the role of bone-modifying agents, ASCO has recommended expanding the use of bisphosphonates to include all patients being treated for active multiple myeloma.

Wolf Emphasizes the Importance of Phrasing in Multiple Myeloma

May 17th 2018

Jeffrey Wolf, MD, emphasizes the importance of identifying risk when diagnosing patients with multiple myeloma.

Expert Summarizes Strides in Relapsed Myeloma, Says More to Come

May 8th 2018

Peter Voorhees, MD, discusses treatments for patients with early relapsed multiple myeloma and previews future research efforts.

Dr. Berdeja on FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma

May 8th 2018

Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of frontline daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

FDA Approves Frontline Daratumumab/VMP Combo for Multiple Myeloma

May 8th 2018

The FDA has approved daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Dr. Bergsagel on Treatment Options for Relapsed/Refractory Myeloma

May 7th 2018

Leif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses treatment options for patients with relapsed/refractory multiple myeloma.

Usmani Discusses MRD and Other Myeloma Developments

May 2nd 2018

Saad Z. Usmani, MD, discusses the clinical applications of minimal residual disease and managing patients with relapsed/refractory multiple myeloma.

Selinexor Again Shows Promise in Heavily Pretreated Myeloma

May 2nd 2018

Selinexor induced an overall response rate of 25.4% in patients with penta-refractory multiple myeloma, according to top-line results from part 2 of the phase IIb STORM trial.

Dr. Wolf Discusses High-Risk Multiple Myeloma

May 2nd 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses high-risk multiple myeloma.

Dr. Usmani on PD-1/PD-L1 Inhibitors in Hematologic Malignancies

April 30th 2018

Saad Z. Usmani, MD, clinical professor of medicine, UNC-Chapel Hill School of Medicine, chief, Plasma Cell Disorders Program, director, clinical research in hematologic malignancies, Levine Cancer Institute, discusses the evolution of PD-1/PD-L1 inhibitors in the treatment of patients with hematologic malignancies.

European Panel Backs Carfilzomib Label Update in Myeloma

April 30th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended adding final overall survival data from the phase III ASPIRE trial to the label for carfilzomib for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma

April 28th 2018

Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

Expert Explains Shifting Myeloma Paradigm

April 27th 2018

Keith Stewart, MB, ChB, discusses the role of stem cell transplant, minimal residual disease testing, and maintenance therapy in the treatment of patients with multiple myeloma.

Options Continue to Emerge for Transplant-Ineligible Multiple Myeloma

April 26th 2018

Nitya Nathwani, MD, highlights current treatment options for transplant-ineligible multiple myeloma, as well as combinations on the horizon.

Dr. Usmani on Minimal Residual Disease in Multiple Myeloma

April 25th 2018

Saad Z. Usmani, MD, clinical professor of medicine, UNC-Chapel Hill School of Medicine, chief, Plasma Cell Disorders Program, director, clinical research in hematologic malignancies, Levine Cancer Institute, discusses the impact of minimal residual disease (MRD) on clinical practice.

Dr. Bergsagel on Competing Philosophies of Treatment in Patients With Relapsed Myeloma

April 24th 2018

Leif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses competing strategies in treating patients with relapsed multiple myeloma.